• FAQ
  • DEMANDER UN RENDEZ-VOUS
HOTLINE (+212) 05 22 86 03 36 / (+212) 06 59 27 33 92
HealthFlex

LABORATOIRE ANOUAL

×
  • Accueil
  • A Propos
    • Qui sommes-nous ?
    • Politique qualite
    • Locaux et environnement
  • Activités
    • Biochimie
    • Hématologie
    • Hormonologie
    • Immunologie
    • Microbiologie
    • Biologie Moléculaire
      • DPNI
      • Rhésus Foétal Anti-D (RhD)
    • Dépistage néonatal
  • Espace patients
    • PRÉPAREZ VOTRE VISITE AU LABORATOIRE
      • Venir à jeun
      • à quelle heure?
      • Des urines de 24h, comment dois-je procéder ?
      • Quels documents apporter ?
    • Prélèvement à réaliser vous-même
    • Questions-réponses
    • Questionnaire de satisfaction
  • Espace préleveurs
    • Manuel de prélèvement
    • Documents à télécharger
  • Recherche scientifique
    • Publications
      • DISTRIBUTION OF KRAS AND BRAF MUTATIONS IN MOROCCAN PATIENTS WITH ADVANCED COLORECTAL CANCER.
      • First application of next-generation sequencing in Moroccan breast/ovarian cancer families and report of a novel frameshift mutation of the BRCA1 gene.
      • Identification of a Novel Nonsense Variant in the SCN1A Gene that Causes Febrile Seizure Disorder
    • Communication
  • Contact

Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer.

19 décembre 2017anoualPublication

Marchoudi N1, Amrani Hassani Joutei H, Jouali F, Fekkak J, Rhaissi H.

Abstract

Targeted therapies have an increasing importance in digestive oncology. To our knowledge, we are the first to report the distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer (CRC) in order to introduce targeted therapy in the arsenal of therapeutic modalities for management of this cancer in Morocco. In this study, 92 samples obtained from patients with CRC were tested for the presence of the nine most common mutations in the KRAS gene and BRAF gene. Among the tested patients, 76.09% of patients had wt-KRAS genotype and 23.91% were KRAS mutants and the majority of mutations would result in an amino acid substitution of glycine by aspartic acid (68.2%) The predominant mutations are G>A transitions and G>T transversions. Around 5% (5.43%) of the tested patients bore the V600E mutation in BRAF gene. Only one patient showing to have the V600E mutation in BRAF was also mutated-KRAS. Summing up the results about the KRAS and the BRAF mutation carriers from our study, the portion of potentially non responsive patients for the anti-EGFR treatment is 28.26%.

KEYWORDS:

BRAF mutation; Cancer colorectal; Colorectal cancer; KRAS mutation; Mutation du BRAF; Mutation du KRAS

https://www.ncbi.nlm.nih.gov/pubmed/23849768

Add Comment Cancel


Articles récents

  • First application of next-generation sequencing in Moroccan breast/ovarian cancer families and report of a novel frameshift mutation of the BRCA1 gene.
  • Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer.

Archives

  • décembre 2017

Catégories

  • Publication

logo

Le laboratoire ANOUAL vous accueille toute la journée de 7h30 à 18h30.

+212 5 22 86 03 36 / +212 5 22 86 28 73

info@labanoual.ma

Boulevard d'Alexandrie, Casablanca 20360, Maroc

Actualités

  • First application of next-generation sequencing in Moroccan breast/ovarian cancer families and report of a novel frameshift mutation of the BRCA1 gene. Déc 19

  • Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Déc 19

Copyright ©2017 all rights reserved